---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023666"
form_type: "8-K"
ticker: "VYCO"
cik: "0001424768"
company_name: "VYCOR MEDICAL INC"
filed_at: "2026-05-15T19:42:28+00:00"
generated_at: "2026-05-15T19:45:11.318813+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vycor Medical Q1 2026 revenue up 5% to $458,540; turns to operating profit of $45,808

## Summary
- Revenue $458,540 (+5% YoY); Vycor Medical division contributed $440,441.
- Operating profit of $45,808 vs operating loss of $(12,806) in Q1 2025.
- Non-GAAP operating profit $59,788, up from $20,388 YoY; cash expenses down to $315,365.
- Gross margin steady at 82% for Vycor Medical; two new peer-reviewed VBAS studies published.
- NovaVision revenue $18,099, still in development stage.

## SEC filing metadata
- accession: 0001493152-26-023666
- form_type: 8-K
- ticker: VYCO
- cik: 0001424768
- company_name: VYCOR MEDICAL INC
- filed_at: 2026-05-15T19:42:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1424768/000149315226023666/0001493152-26-023666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1424768/000149315226023666/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023666
- JSON: https://secwatch.observer/filing/0001493152-26-023666.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023666.txt

## Key facts
- Earnings Releases
  VYCOR MEDICAL INC reported the three months ended March 31, 2026 results: revenue $458,540.
  - Period: the three months ended March 31, 2026
  - Revenue: $458,540
  - Result: reported results
  source text: the traditional blade retractor group, implying safer tumor resection using VBAS. Financial Results For the three months ended March 31, 2026, the Company reported revenue of $458,540, an increase of $22,162 (or 5%) over the 2025 period. The Vycor Medical division (VBAS) generated revenue of $440,441, an increase of $21,921 (or 5%) over the 2025 period. Most of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1424768/000149315226023666/0001493152-26-023666-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.